BGMA Chief Samuels Sees Boost From UK Biosimilars Pathway

Also Sets Out Aspirations For Repurposing Project And COVID Expectations

 
• By Dave Wallace

In the second part of an exclusive interview with Generics Bulletin, BGMA chief executive Mark Samuels talks about the UK’s new biosimilars licensing pathway, future trade deals and IP, and efforts around repurposing generics, as well as looking ahead to how the UK’s vaccination program could reshape the COVID-19 pandemic.

Mark Samuels, BGMA CEO
Mark Samuels sees the new MHRA biosimilars pathway as a “win-win” for developers and the NHS • Source: BGMA

The UK’s Medicines and Healthcare products Regulatory Agency is “leading the world” with its new biosimilars licensing pathway that will not typically require comparative efficacy data and will consider approved biosimilars interchangeable with their reference products for all indications, according to Mark Samuels, CEO of the British Generic Manufacturers Association.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products